Related Experiment Video
Updated: Jun 3, 2026
09:52
Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
End points for cisplatin ototoxicity.
Kaiser Qureshy1, Brian Blakley, Saad Alsaleh
1University of Manitoba, and Sylvie Berard: Health Sciences Centre, Winnipeg, MB.
Summary
Hearing loss from cisplatin is variable and may improve over time in mice, unlike in guinea pigs. This suggests ototoxicity recovery should be studied long-term for potential preventive treatments.
Area of Science:
- Ototoxicity research
- Comparative animal studies
Background:
- Human ototoxicity from agents like cisplatin is often considered permanent.
- Previous studies primarily assessed hearing loss effects over short durations (days/weeks).
Purpose of the Study:
- To investigate long-term hearing recovery in mice and guinea pigs after cisplatin exposure.
- To compare species-specific responses to ototoxic agents.
Main Methods:
- Mice and guinea pigs received cisplatin (15 mg/kg) or saline.
- Auditory Brainstem Response (ABR) testing was conducted over 8 months in mice and 1 month in guinea pigs.
Main Results:
- Cisplatin-induced hearing loss varied significantly between and within species.
- Mice showed maximal hearing loss (~17 dB) at 3 months, with subsequent improvement.
- Guinea pigs experienced greater hearing loss (~25 dB) within 1 month.
Conclusions:
- Otoxicity endpoints require assessment beyond 1 month post-exposure in animal models.
- Incomplete hearing loss before 1 month in mice suggests a window for preventive treatment studies.
Related Concept Videos
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...